AstraZeneca licenses genetic disease drug to Mereo BioPharma

LONDON (Reuters) - Mereo BioPharma has agreed a licensing deal and acquisition option for a rare disease drug from AstraZeneca as the big drugmaker continues to divest non-core assets.